Literature DB >> 10233631

Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy.

U Wollina, A Looks, R Schneider, B Maak.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 10233631     DOI： 10.1046/j.1365-2230.1998.00378.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  6 in total

Review 1.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 2.  Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

Authors:  Han Jie Soh; Courtney Samuel; Victoria Heaton; William Douglas Renton; Angela Cox; Jane Munro
Journal:  Rheumatol Int       Date:  2019-03-05       Impact factor: 2.631

Review 3.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

4.  Pansclerotic morphea in childhood: a case report.

Authors:  T Doede; U Wollina; W Hindermann; F Schier; M Bondartschuk
Journal:  Pediatr Surg Int       Date:  2003-06-21       Impact factor: 1.827

5.  The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis.

Authors:  Marta Baleva; Krasimir Nikolov
Journal:  Int J Rheumatol       Date:  2011-11-02

Review 6.  Update on Management of Morphea (Localized Scleroderma) in Children.

Authors:  Renu George; Anju George; T Sathish Kumar
Journal:  Indian Dermatol Online J       Date:  2020-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.